Clinical Trials
4
Active:0
Completed:0
Trial Phases
1 Phases
Phase 2:4
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 2
4 (100.0%)Efficacy, Safety, and Pharmacokinetics of ES-481 in Adult Patients With Essential Tremors
- First Posted Date
- 2022-02-10
- Last Posted Date
- 2023-03-02
- Lead Sponsor
- ES Therapeutics Australia Pty Ltd
- Target Recruit Count
- 24
- Registration Number
- NCT05234762
- Locations
- 🇨🇦
Clinique Neuro-Levis, Levis, Quebec, Canada
ES-481 for Uncontrolled Glioma-Associated Epilepsy and Assessment for Potential Anti-Tumorigenic Effect in Patients With Isocitrate Dehydrogenase 1 (IDH1) Mutant Tumors
- First Posted Date
- 2021-02-03
- Last Posted Date
- 2022-04-06
- Lead Sponsor
- ES Therapeutics Australia Pty Ltd
- Registration Number
- NCT04737174
Efficacy, Safety and Pharmacokinetics of ES-481 in Adult Patients With Drug Resistant Epilepsy
Phase 2
Recruiting
- Conditions
- Drug Resistant Epilepsy
- Interventions
- First Posted Date
- 2021-01-20
- Last Posted Date
- 2023-03-02
- Lead Sponsor
- ES Therapeutics Australia Pty Ltd
- Target Recruit Count
- 24
- Registration Number
- NCT04714996
- Locations
- 🇦🇺
Royal Brisbane and Women's Hospital, Herston, Queensland, Australia
🇦🇺Austin Hospital, Heidelberg, Victoria, Australia
🇦🇺Alfred Health, Melbourne, Victoria, Australia
News
No news found